Xinhua Pharmaceutical Wins Approval for Epinephrine Hydrochloride Injection in China
Shandong Xinhua Pharmaceutical Company Limited announced that its Epinephrine Hydrochloride Injection has received approval from China's National Medical Products Administration, enhancing its market competitiveness. This approval follows the Consistency of Quality and Efficacy Evaluation for Generic Drugs. The announcement was made via the Hong Kong Stock Exchange's Issuer Information Service.
Shandong Xinhua Pharmaceutical Company Limited has announced that its Epinephrine Hydrochloride Injection has passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs, as approved by the National Medical Products Administration of China. This regulatory approval is expected to enhance the product’s market competitiveness. No other organizations are mentioned as recipients of this approval. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Xinhua Pharmaceutical Company Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251127-11930095), on November 27, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
